Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation
Open Access
- 5 October 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (5) , 5751-5763
Abstract
Background: XPO1 mediates the nuclear export of several proteins, mainly tumor suppressors. KPT‐330 (Selinexor) is a selective inhibitor of XPO1 that has demonstrated good therapeutic effects in hematologic cancers.Methods: We used TCGA and GTEx pan‐cancer database to evaluate XPO1 mRNA expression in various tumors. Cell proliferation assay and colony formation assay were used to analyze the in vitro antitumor effects of XPO1 inhibitor KPT‐330. Western blot was performed to explore the specific mechanisms.Results: We found that XPO1 was highly expressed across a range of cancers and associated with poor prognosis in hepatobiliary and pancreatic tumors. We revealed that the XPO1 inhibitor KPT‐330 triggered the nuclear accumulation of the p53 protein and significantly disrupted the proliferation of cholangiocarcinoma cells. Mechanistically, the XPO1 inhibitor, KPT‐330, reduced BIRC6 expression by inhibiting the PI3K/AKT pathway to decrease p53 degradation and improve its stability.Conclusion: Therefore, XPO1 may be a potential therapeutic target in cholangiocarcinoma, mediated by its effects on KPT‐330.Keywords
Funding Information
- National Natural Science Foundation of China (31701108, 81974371, 82002503, 82172628, 82173081)
This publication has 26 references indexed in Scilit:
- Structural prerequisites for CRM1-dependent nuclear export signaling peptides: accessibility, adapting conformation, and the stability at the binding siteScientific Reports, 2019
- The past, present, and future of CRM1/XPO1 inhibitorsStem Cell Investigation, 2019
- PI3K signaling in cancer: beyond AKTCurrent Opinion in Cell Biology, 2017
- Structural determinants of nuclear export signal orientation in binding to exportin CRM1eLife, 2015
- Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) proteinPharmacology & Therapeutics, 2015
- BIRC6 promotes hepatocellular carcinogenesis: Interaction of BIRC 6 with p53 facilitating p53 degradationInternational Journal of Cancer, 2014
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276Leukemia, 2013
- A Human IAP-Family Gene, Apollon, Expressed in Human Brain Cancer CellsBiochemical and Biophysical Research Communications, 1999
- Phase I trial of elactocinBritish Journal of Cancer, 1996
- Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression.Journal of Biological Chemistry, 1994